31 related articles for article (PubMed ID: 16497565)
1. Stereoselective separation of omeprazole and 5-hydroxy-omeprazole using dried plasma spots and a heart-cutting 2D-LC approach for accurate CYP2C19 phenotyping.
Abouir K; Samer C; Landry R; Varesio E; Daali Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Jan; 1232():123962. PubMed ID: 38096743
[TBL] [Abstract][Full Text] [Related]
2. Buspirone, fexofenadine, and omeprazole: quantification of probe drugs and their metabolites in human plasma.
Gor P; Alnouti Y; Reed GA
J Pharm Biomed Anal; 2011 Jul; 55(5):1127-35. PubMed ID: 21546194
[TBL] [Abstract][Full Text] [Related]
3. Ecofriendly HPLC Method for Simultaneous Determination of the Co-Prescribed Drugs in Chemotherapy Omeprazole, Ondansetron and Deflazacort in Spiked Human Plasma.
Abdallah FF; Fatma M; Gouda AM; Abdelaleem EA; Emam AA
J Chromatogr Sci; 2023 Nov; ():. PubMed ID: 37997391
[TBL] [Abstract][Full Text] [Related]
4. A Rapid and Sensitive HPLC-Fluorescence Method for Determination of Mirtazapine and Its two Major Metabolites in Human Plasma.
Lavasani H; Giorgi M; Sheikholeslami B; Hedayati M; Rouini MR
Iran J Pharm Res; 2014; 13(3):853-62. PubMed ID: 25276185
[TBL] [Abstract][Full Text] [Related]
5. Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21.
Sychterz C; Gardner I; Chiang M; Rachumallu R; Neuhoff S; Perera V; Merali S; Schmidt BJ; Gaohua L
Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295903
[TBL] [Abstract][Full Text] [Related]
6. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.
Park S; Hyun YJ; Kim YR; Lee JH; Ryu S; Kim JM; Oh WY; Na HS; Lee JG; Seo DW; Hwang IY; Park Z; Jang IJ; Oh J; Choi SE
J Korean Med Sci; 2017 May; 32(5):729-736. PubMed ID: 28378544
[TBL] [Abstract][Full Text] [Related]
7. Complexity in estimation of esomeprazole and its related impurities' stability in various stress conditions in low-dose aspirin and esomeprazole magnesium capsules.
Reddy PS; Hotha KK; Sait S
Sci Pharm; 2013; 81(2):475-92. PubMed ID: 23833714
[TBL] [Abstract][Full Text] [Related]
8. The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
Yamada S; Shiohira H; Yasui-Furukori N; Tateishi T; Akamine Y; Uno T
Eur J Clin Pharmacol; 2013 Jul; 69(7):1423-8. PubMed ID: 23435615
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive development strategy in buccal drug delivery.
Figueiras A; Pais AA; Veiga FJ
AAPS PharmSciTech; 2010 Dec; 11(4):1703-12. PubMed ID: 21116750
[TBL] [Abstract][Full Text] [Related]
10. The role of L-arginine in inclusion complexes of omeprazole with cyclodextrins.
Figueiras A; Sarraguça JM; Pais AA; Carvalho RA; Veiga JF
AAPS PharmSciTech; 2010 Mar; 11(1):233-40. PubMed ID: 20135244
[TBL] [Abstract][Full Text] [Related]
11. Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
Sugimoto K; Uno T; Yamazaki H; Tateishi T
Br J Clin Pharmacol; 2008 Mar; 65(3):437-9. PubMed ID: 18241287
[TBL] [Abstract][Full Text] [Related]
12. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
Sugimoto K; Uno T; Tateishi T
Eur J Clin Pharmacol; 2008 Jun; 64(6):583-7. PubMed ID: 18214455
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole stimulates the induction of human insulin-like growth factor binding protein-1 through aryl hydrocarbon receptor activation.
Murray IA; Perdew GH
J Pharmacol Exp Ther; 2008 Mar; 324(3):1102-10. PubMed ID: 18055878
[TBL] [Abstract][Full Text] [Related]
14. Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
Niioka T; Uno T; Sugimoto K; Sugawara K; Hayakari M; Tateishi T
Eur J Clin Pharmacol; 2007 Nov; 63(11):1031-8. PubMed ID: 17701405
[TBL] [Abstract][Full Text] [Related]
15. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
Uno T; Niioka T; Hayakari M; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2007 Feb; 63(2):143-9. PubMed ID: 17203292
[TBL] [Abstract][Full Text] [Related]
16. Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.
Shimizu M; Uno T; Niioka T; Yaui-Furukori N; Takahata T; Sugawara K; Tateishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Mar; 832(2):241-8. PubMed ID: 16497565
[TBL] [Abstract][Full Text] [Related]
17. Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes.
Shiohira H; Yasui-Furukori N; Tateishi T; Uno T
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2465-70. PubMed ID: 21783435
[TBL] [Abstract][Full Text] [Related]
18. Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.
González HM; Romero EM; Chavez Tde J; Peregrina AA; Quezada V; Hoyo-Vadillo C
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(2):459-65. PubMed ID: 12401374
[TBL] [Abstract][Full Text] [Related]
19. Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Uno T; Yasui-Furukori N; Takahata T; Sugawara K; Tateishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):309-14. PubMed ID: 15664363
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
